Alyeska Investment Group
SGMT icon

Alyeska Investment Group’s Sagimet Biosciences SGMT Stock Holding History

Alyeska Investment Group’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,192,443
Closed -$3.89M – 659
2025
Q1 		$3.89M Sell
1,192,443
-98,069
-8% -$411K 0.02% 376
2024
Q4 		$5.81M Sell
1,290,512
-87,846
-6% -$445K 0.02% 391
2024
Q3 		$3.82M Buy
1,378,358
+100,000
+8% +$308K 0.02% 373
2024
Q2 		$4.37M Buy
1,278,358
+180,145
+16% +$826K 0.03% 355
2024
Q1 		$5.95M Buy
1,098,213
+611,653
+126% +$4.39M 0.04% 313
2023
Q4 		$2.64M Buy
486,560
+246,531
+103% +$1.16M 0.02% 353
2023
Q3 		$2.11M Buy
+240,029
New +$3.2M 0.01% 385

Other funds holding SGMT

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return

Alyeska Investment Group's SGMT Position: Q2 2025 in Review

Alyeska Investment Group sold out of Sagimet Biosciences (SGMT) in Q2 2025, closing a stake of 1,192,443 shares — an estimated $3.89M sold.

Alyeska Investment Group first reported a position in SGMT in Q3 2023 and held it in 7 quarters. The position peaked at $5.95M in Q1 2024. 67 funds tracked by Wall St. Rank hold SGMT as of Q2 2025.

  • Alyeska Investment Group reported no remaining Sagimet Biosciences position as of Q2 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 1,192,443 Sagimet Biosciences shares in Q2 2025, an estimated $3.89M.
  • Alyeska Investment Group first reported a position in Sagimet Biosciences in Q3 2023 and held it in 7 quarters.
  • Alyeska Investment Group's Sagimet Biosciences position peaked at $5.95M in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2025.

Based on Alyeska Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.